Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Lung Cancer

Free Subscription Articles published in J Cancer Res Clin Oncol Retrieve available abstracts of 219 articles: HTML format

Single Articles

April 2021
1. WEI T, Song J, Liang K, Li L, et al
   Identification of a novel therapeutic candidate, NRK, in primary cancer-associated fibroblasts of lung adenocarcinoma microenvironment.
   J Cancer Res Clin Oncol. 2021;147:1049-1064.
   PubMed     Abstract available
   
   
   
2. ZHANG G, Cao Y, Zhang J, Zhao Z, et al
   Epidermal growth factor receptor mutations in lung adenocarcinoma: associations between dual-energy spectral CT measurements and histologic results.
   J Cancer Res Clin Oncol. 2021;147:1169-1178.
   PubMed     Abstract available
   
   
   March 2021
3. HARA N, Ichihara E, Harada D, Inoue K, et al
   Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
   J Cancer Res Clin Oncol. 2021 Mar 29. pii: 10.1007/s00432-021-03615.
   PubMed     Abstract available
   
   
   
4. PATEL MA, Fazli Y, Sivakumar S, Dennis C, et al
   Brachytherapy vs external beam therapy among NSCLC patients undergoing limited surgical resection.
   J Cancer Res Clin Oncol. 2021;147:853-861.
   PubMed     Abstract available
   
   
   
5. HUANG D, Cui P, Huang Z, Wu Z, et al
   Anti-PD-1/L1 plus anti-angiogenesis therapy as second-line or later treatment in advanced lung adenocarcinoma.
   J Cancer Res Clin Oncol. 2021;147:881-891.
   PubMed     Abstract available
   
   
   
6. LIN M, Qu M, Huang W, Liu T, et al
   Clinical effectiveness of percutaneous vertebroplasty in conjunction with postoperative radiotherapy in the treatment of spinal metastases.
   J Cancer Res Clin Oncol. 2021;147:835-844.
   PubMed     Abstract available
   
   
   February 2021
7. FENG M, Ye X, Chen B, Zhang J, et al
   Detection of circulating genetically abnormal cells using 4-color fluorescence in situ hybridization for the early detection of lung cancer.
   J Cancer Res Clin Oncol. 2021 Feb 6. pii: 10.1007/s00432-021-03517.
   PubMed     Abstract available
   
   
   
8. BILGIN B, Sendur MAN, Yucel S, Hizal M, et al
   The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement.
   J Cancer Res Clin Oncol. 2021 Feb 2. pii: 10.1007/s00432-021-03546.
   PubMed     Abstract available
   
   
   
9. PARK JH, You GL, Ahn MJ, Kim SW, et al
   Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05.
   J Cancer Res Clin Oncol. 2021 Feb 1. pii: 10.1007/s00432-021-03527.
   PubMed     Abstract available
   
   
   
10. BI Y, Jiang Y, Li X, Hou G, et al
    Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/beta-catenin signaling and autophagy.
    J Cancer Res Clin Oncol. 2021;147:499-505.
    PubMed     Abstract available
    
    
    
11. CHANG Y, Zhao C, Ding H, Wang T, et al
    Serum factor(s) from lung adenocarcinoma patients regulates the molecular clock expression.
    J Cancer Res Clin Oncol. 2021;147:493-498.
    PubMed     Abstract available
    
    
    
12. CAROSIO R, Fontana V, Mastracci L, Ferro P, et al
    Characterization of soluble PD-L1 in pleural effusions of mesothelioma patients: potential implications in the immune response and prognosis.
    J Cancer Res Clin Oncol. 2021;147:459-468.
    PubMed     Abstract available
    
    
    January 2021
13. LI X, Liu L, Song X, Wang K, et al
    TEP linc-GTF2H2-1, RP3-466P17.2, and lnc-ST8SIA4-12 as novel biomarkers for lung cancer diagnosis and progression prediction.
    J Cancer Res Clin Oncol. 2021 Jan 29. pii: 10.1007/s00432-020-03502.
    PubMed     Abstract available
    
    
    
14. YANG M, Li Z, Tao J, Hu H, et al
    Resveratrol induces PD-L1 expression through snail-driven activation of Wnt pathway in lung cancer cells.
    J Cancer Res Clin Oncol. 2021 Jan 20. pii: 10.1007/s00432-021-03510.
    PubMed     Abstract available
    
    
    
15. NOUNU A, Walker V, Richmond RC
    Letter regarding, "Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses".
    J Cancer Res Clin Oncol. 2021 Jan 12. pii: 10.1007/s00432-020-03508.
    PubMed    
    
    
    
16. BILGIN B, Sendur MAN, Yucel S, Celik E, et al
    Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
    J Cancer Res Clin Oncol. 2021 Jan 12. pii: 10.1007/s00432-020-03501.
    PubMed     Abstract available
    
    
    
17. FU F, Zhang Y, Gao Z, Zhao Y, et al
    Combination of CD47 and CD68 expression predicts survival in eastern-Asian patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2021 Jan 4. pii: 10.1007/s00432-020-03477.
    PubMed     Abstract available
    
    
    
18. XIN S, Fang W, Li J, Li D, et al
    Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients.
    J Cancer Res Clin Oncol. 2021 Jan 2. pii: 10.1007/s00432-020-03476.
    PubMed     Abstract available
    
    
    
19. MATSUBARA T, Yamaguchi M, Jinnouchi M, Takamori S, et al
    Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis.
    J Cancer Res Clin Oncol. 2021 Jan 2. pii: 10.1007/s00432-020-03478.
    PubMed     Abstract available
    
    
    
20. WU Z, Huang T, Zhang S, Cheng D, et al
    A prediction model to evaluate the pretest risk of malignancy in solitary pulmonary nodules: evidence from a large Chinese southwestern population.
    J Cancer Res Clin Oncol. 2021;147:275-285.
    PubMed     Abstract available
    
    
    
21. MASUDA K, Horinouchi H, Tanaka M, Higashiyama R, et al
    Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.
    J Cancer Res Clin Oncol. 2021;147:245-251.
    PubMed     Abstract available
    
    
    December 2020
22. NADLER E, Arondekar B, Aguilar KM, Zhou J, et al
    Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study.
    J Cancer Res Clin Oncol. 2020 Dec 2. pii: 10.1007/s00432-020-03414.
    PubMed     Abstract available
    
    
    November 2020
23. RACHOW T, Schiffl H, Lang SM
    Risk of lung cancer and renin-angiotensin blockade: a concise review.
    J Cancer Res Clin Oncol. 2020 Nov 24. pii: 10.1007/s00432-020-03445.
    PubMed     Abstract available
    
    
    
24. SHU Z, Dong B, Shi L, Shen W, et al
    Correction to: Stereotactic body radiotherapy for elderly patients (>/= 75 years) with earlystage nonsmall cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Nov 23. pii: 10.1007/s00432-020-03469.
    PubMed     Abstract available
    
    
    
25. HAO S, Liu J, Ma J
    Further discussion on the association between desmoglein 2 and tumor size of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Nov 22. pii: 10.1007/s00432-020-03465.
    PubMed     Abstract available
    
    
    
26. ZHENG Q, Huang Y, Zeng X, Chen X, et al
    Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
    J Cancer Res Clin Oncol. 2020 Nov 16. pii: 10.1007/s00432-020-03444.
    PubMed     Abstract available
    
    
    
27. ARAGAKI M, Hida Y, Kato T, Fujiwara-Kuroda A, et al
    Feasibility of limited resection for peripheral small-sized non-small cell lung cancer: a retrospective single-center-based study.
    J Cancer Res Clin Oncol. 2020 Nov 5. pii: 10.1007/s00432-020-03441.
    PubMed     Abstract available
    
    
    
28. CHEN S, Bao Y, Xu J, Zhang X, et al
    Efficacy and safety of TCM combined with chemotherapy for SCLC: a systematic review and meta-analysis.
    J Cancer Res Clin Oncol. 2020;146:2913-2935.
    PubMed     Abstract available
    
    
    
29. WANG F, Zhao N, Gao G, Deng HB, et al
    Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2020;146:2851-2859.
    PubMed     Abstract available
    
    
    
30. YANG J, Wu Z, Chen Y, Hu C, et al
    Pre-treatment with Bifidobacterium infantis and its specific antibodies enhance targeted radiosensitization in a murine model for lung cancer.
    J Cancer Res Clin Oncol. 2020 Nov 1. pii: 10.1007/s00432-020-03434.
    PubMed     Abstract available
    
    
    October 2020
31. LI L, Pan Y, Mo X, Wei T, et al
    A novel metastatic promoter CEMIP and its downstream molecular targets and signaling pathway of cellular migration and invasion in SCLC cells based on proteome analysis.
    J Cancer Res Clin Oncol. 2020;146:2519-2534.
    PubMed     Abstract available
    
    
    
32. TAKADA K, Toyokawa G, Kinoshita F, Jogo T, et al
    Expression of PD-L1, PD-L2, and IDO1 on tumor cells and density of CD8-positive tumor-infiltrating lymphocytes in early-stage lung adenocarcinoma according to histological subtype.
    J Cancer Res Clin Oncol. 2020;146:2639-2650.
    PubMed     Abstract available
    
    
    September 2020
33. SAKAI T, Udagawa H, Matsumoto S, Yoh K, et al
    Morphological, immune and genetic features in biopsy sample associated with the efficacy of pembrolizumab in patients with non-squamous non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Sep 30. pii: 10.1007/s00432-020-03413.
    PubMed     Abstract available
    
    
    
34. XIAN W, Shen J, Zhou H, Liu J, et al
    Mendelian randomization study indicates lack of causal relationship between physical activity and lung cancer.
    J Cancer Res Clin Oncol. 2020 Sep 28. pii: 10.1007/s00432-020-03409.
    PubMed     Abstract available
    
    
    
35. JIANG Y, Su Z, Li C, Wang R, et al
    Association between the use of aspirin and risk of lung cancer: results from pooled cohorts and Mendelian randomization analyses.
    J Cancer Res Clin Oncol. 2020 Sep 23. pii: 10.1007/s00432-020-03394.
    PubMed     Abstract available
    
    
    
36. LI Q, Zhu X, Song W, Peng X, et al
    The P2X7 purinergic receptor: a potential therapeutic target for lung cancer.
    J Cancer Res Clin Oncol. 2020 Sep 5. pii: 10.1007/s00432-020-03379.
    PubMed     Abstract available
    
    
    
37. ZHOU X, Xu X, Tian Z, Xu WY, et al
    Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing.
    J Cancer Res Clin Oncol. 2020;146:2277-2287.
    PubMed     Abstract available
    
    
    
38. LIU J, Yang X, Zhang L, Yang B, et al
    Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2020;146:2299-2310.
    PubMed     Abstract available
    
    
    
39. FRANZESE C, Bonu ML, Comito T, Clerici E, et al
    Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    J Cancer Res Clin Oncol. 2020;146:2289-2297.
    PubMed     Abstract available
    
    
    
40. KIM SA, Kim JW, Suh KJ, Chang W, et al
    Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
    J Cancer Res Clin Oncol. 2020;146:2399-2410.
    PubMed     Abstract available
    
    
    
41. ZHANG Y, Deng C, Ma X, Gao Z, et al
    Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy.
    J Cancer Res Clin Oncol. 2020;146:2411-2417.
    PubMed     Abstract available
    
    
    August 2020
42. ZHOU L, Zhang M, Li R, Xue J, et al
    Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.
    J Cancer Res Clin Oncol. 2020 Aug 28. pii: 10.1007/s00432-020-03360.
    PubMed     Abstract available
    
    
    
43. MA X, Wang S, Zhang Y, Wei H, et al
    Efficacy and safety of immune checkpoint inhibitors (ICIs) in extensive-stage small cell lung cancer (SCLC).
    J Cancer Res Clin Oncol. 2020 Aug 27. pii: 10.1007/s00432-020-03362.
    PubMed     Abstract available
    
    
    
44. DU TQ, Li X, Zhong WS, Tian JD, et al
    Brain metastases of lung cancer: comparison of survival outcomes among whole brain radiotherapy, whole brain radiotherapy with consecutive boost, and simultaneous integrated boost.
    J Cancer Res Clin Oncol. 2020 Aug 26. pii: 10.1007/s00432-020-03359.
    PubMed     Abstract available
    
    
    
45. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
    Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
    J Cancer Res Clin Oncol. 2020 Aug 6. pii: 10.1007/s00432-020-03344.
    PubMed     Abstract available
    
    
    July 2020
46. CHEN SS, Li K, Wu J, Peng ZY, et al
    Stem signatures associated antibodies yield early diagnosis and precise prognosis predication of patients with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Jul 20. pii: 10.1007/s00432-020-03325.
    PubMed     Abstract available
    
    
    
47. LATHWAL A, Kumar R, Arora C, Raghava GPS, et al
    Identification of prognostic biomarkers for major subtypes of non-small-cell lung cancer using genomic and clinical data.
    J Cancer Res Clin Oncol. 2020 Jul 14. pii: 10.1007/s00432-020-03318.
    PubMed     Abstract available
    
    
    
48. BIAN J, Yan K, Liu N, Xu X, et al
    Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucose positron emission tomography uptake in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Jul 13. pii: 10.1007/s00432-020-03244.
    PubMed     Abstract available
    
    
    
49. HUO Y, Guo Z, Gao X, Liu Z, et al
    Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules.
    J Cancer Res Clin Oncol. 2020 Jul 9. pii: 10.1007/s00432-020-03309.
    PubMed     Abstract available
    
    
    
50. LANDRE T, Des Guetz G, Chouahnia K, Duchemann B, et al
    First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation.
    J Cancer Res Clin Oncol. 2020 Jul 7. pii: 10.1007/s00432-020-03311.
    PubMed     Abstract available
    
    
    
51. KO KH, Huang HK, Chen YI, Chang H, et al
    Surgical outcomes of second primary lung cancer after the extrapulmonary malignancy.
    J Cancer Res Clin Oncol. 2020 Jul 6. pii: 10.1007/s00432-020-03310.
    PubMed     Abstract available
    
    
    
52. ZENG Y, Li N, Liu W, Zeng M, et al
    Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Jul 5. pii: 10.1007/s00432-020-03288.
    PubMed     Abstract available
    
    
    
53. ZHAO Y, Pan Y, Cheng C, Zheng D, et al
    EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis.
    J Cancer Res Clin Oncol. 2020;146:1781-1789.
    PubMed     Abstract available
    
    
    
54. JU Q, Zhao YJ, Ma S, Li XM, et al
    Genome-wide analysis of prognostic-related lncRNAs, miRNAs and mRNAs forming a competing endogenous RNA network in lung squamous cell carcinoma.
    J Cancer Res Clin Oncol. 2020;146:1711-1723.
    PubMed     Abstract available
    
    
    June 2020
55. LI WQ, Cui JW
    Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments.
    J Cancer Res Clin Oncol. 2020 Jun 28. pii: 10.1007/s00432-020-03296.
    PubMed     Abstract available
    
    
    
56. KIM SH, Choi CM, Lee DH, Kim SW, et al
    Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease.
    J Cancer Res Clin Oncol. 2020 Jun 24. pii: 10.1007/s00432-020-03293.
    PubMed     Abstract available
    
    
    
57. XIE J, Zhang X, Hu S, Peng WD, et al
    Effects of adjuvant chemotherapy on survival of patients with stage IB non-small cell lung cancer with visceral pleural invasion.
    J Cancer Res Clin Oncol. 2020 Jun 12. pii: 10.1007/s00432-020-03276.
    PubMed     Abstract available
    
    
    
58. ZHOU H, Sun Y, Xiu W, Han J, et al
    Overall survival benefit of continuing immune checkpoint inhibitors treatment post dissociated response in patients with advanced lung cancer.
    J Cancer Res Clin Oncol. 2020 Jun 9. pii: 10.1007/s00432-020-03282.
    PubMed     Abstract available
    
    
    
59. HUI Z, Wei F, Ren H, Xu W, et al
    Primary tumor standardized uptake value (SUVmax) measured on (18)F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Jun 3. pii: 10.1007/s00432-020-03240.
    PubMed     Abstract available
    
    
    
60. LUO G, Tang M, Zhao Q, Lu L, et al
    Bone marrow adipocytes enhance osteolytic bone destruction by activating 1q21.3(S100A7/8/9-IL6R)-TLR4 pathway in lung cancer.
    J Cancer Res Clin Oncol. 2020 Jun 3. pii: 10.1007/s00432-020-03277.
    PubMed     Abstract available
    
    
    
61. ZHAO M, Chen Z, Zheng Y, Liang J, et al
    Identification of cancer stem cell-related biomarkers in lung adenocarcinoma by stemness index and weighted correlation network analysis.
    J Cancer Res Clin Oncol. 2020;146:1463-1472.
    PubMed     Abstract available
    
    
    
62. WEN Z, Zhao Y, Fu F, Hu H, et al
    Comparison of outcomes following segmentectomy or lobectomy for patients with clinical N0 invasive lung adenocarcinoma of 2 cm or less in diameter.
    J Cancer Res Clin Oncol. 2020;146:1603-1613.
    PubMed     Abstract available
    
    
    May 2020
63. AARNINK A, Fumet JD, Favier L, Truntzer C, et al
    Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.
    J Cancer Res Clin Oncol. 2020 May 30. pii: 10.1007/s00432-020-03262.
    PubMed     Abstract available
    
    
    
64. HAKOZAKI T, Hosomi Y, Shimizu A, Kitadai R, et al
    Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
    J Cancer Res Clin Oncol. 2020 May 27. pii: 10.1007/s00432-020-03252.
    PubMed     Abstract available
    
    
    
65. HAKOZAKI T, Hosomi Y, Kitadai R, Kitagawa S, et al
    Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2020 May 27. pii: 10.1007/s00432-020-03271.
    PubMed     Abstract available
    
    
    
66. ESAGIAN SM, Grigoriadou GIota, Nikas IP, Boikou V, et al
    Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review.
    J Cancer Res Clin Oncol. 2020 May 27. pii: 10.1007/s00432-020-03267.
    PubMed     Abstract available
    
    
    
67. ZHU HZ, Fang CJ, Guo Y, Zhang Q, et al
    Detection of miR-155-5p and imaging lung cancer for early diagnosis: in vitro and in vivo study.
    J Cancer Res Clin Oncol. 2020 May 23. pii: 10.1007/s00432-020-03246.
    PubMed     Abstract available
    
    
    
68. MU Y, Hao X, Xing P, Hu X, et al
    Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    J Cancer Res Clin Oncol. 2020 May 8. pii: 10.1007/s00432-020-03239.
    PubMed     Abstract available
    
    
    
69. RANA RH, Alam F, Alam K, Gow J, et al
    Gender-specific differences in care-seeking behaviour among lung cancer patients: a systematic review.
    J Cancer Res Clin Oncol. 2020;146:1169-1196.
    PubMed     Abstract available
    
    
    
70. CHEN YY, Huang YJ, Huang HK, Chang H, et al
    The prognostic factors of recurrence and survival in female patients with lung adenocarcinoma and breast cancer.
    J Cancer Res Clin Oncol. 2020;146:1299-1306.
    PubMed     Abstract available
    
    
    
71. OKI T, Aokage K, Nomura S, Tane K, et al
    Optimal method for measuring invasive size that predicts survival in invasive mucinous adenocarcinoma of the lung.
    J Cancer Res Clin Oncol. 2020;146:1291-1298.
    PubMed     Abstract available
    
    
    
72. ZHOU C, Li W, Shao J, Zhao J, et al
    Thoracic solitary fibrous tumors: an analysis of 70 patients who underwent surgical resection in a single institution.
    J Cancer Res Clin Oncol. 2020;146:1245-1252.
    PubMed     Abstract available
    
    
    
73. FRANZESE C, Comito T, Franceschini D, Loi M, et al
    Recursive partitioning model-based analysis for survival of colorectal cancer patients with lung and liver oligometastases treated with stereotactic body radiation therapy.
    J Cancer Res Clin Oncol. 2020;146:1227-1234.
    PubMed     Abstract available
    
    
    April 2020
74. LI A, Cao W, Liu X, Zhang Y, et al
    Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells.
    J Cancer Res Clin Oncol. 2020 Apr 27. pii: 10.1007/s00432-020-03228.
    PubMed     Abstract available
    
    
    
75. LIU J, Mao G, Li Y, Tao L, et al
    Targeted deep sequencing helps distinguish independent primary tumors from intrapulmonary metastasis for lung cancer diagnosis.
    J Cancer Res Clin Oncol. 2020 Apr 24. pii: 10.1007/s00432-020-03227.
    PubMed     Abstract available
    
    
    
76. LI N, Zeng Y, Huang J
    Signaling pathways and clinical application of RASSF1A and SHOX2 in lung cancer.
    J Cancer Res Clin Oncol. 2020 Apr 7. pii: 10.1007/s00432-020-03188.
    PubMed     Abstract available
    
    
    
77. YOU H, Zhang YZ, Lai HL, Li D, et al
    Prognostic significance of tumor poliovirus receptor and CTLA4 expression in patients with surgically resected non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Apr 4. pii: 10.1007/s00432-020-03189.
    PubMed     Abstract available
    
    
    
78. GUO W, Sun S, Guo L, Song P, et al
    Elevated TOP2A and UBE2C expressions correlate with poor prognosis in patients with surgically resected lung adenocarcinoma: a study based on immunohistochemical analysis and bioinformatics.
    J Cancer Res Clin Oncol. 2020;146:821-841.
    PubMed     Abstract available
    
    
    
79. MORMILE R
    Hyperthermia, positive feedback loop with IL-6 and risk of NSCLC progression: a tangle to unravel?
    J Cancer Res Clin Oncol. 2020;146:1101-1102.
    PubMed     Abstract available
    
    
    March 2020
80. CHEN H, Wang A, Wang J, He Z, et al
    Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.
    J Cancer Res Clin Oncol. 2020 Mar 27. pii: 10.1007/s00432-020-03192.
    PubMed     Abstract available
    
    
    
81. NI Y, Ye X, Yang X, Huang G, et al
    Microwave ablation for non-small cell lung cancer with synchronous solitary extracranial metastasis.
    J Cancer Res Clin Oncol. 2020 Mar 7. pii: 10.1007/s00432-020-03176.
    PubMed     Abstract available
    
    
    
82. LIU Y, Wu S, Shi X, Liang Z, et al
    ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm.
    J Cancer Res Clin Oncol. 2020 Mar 3. pii: 10.1007/s00432-020-03166.
    PubMed     Abstract available
    
    
    
83. LI S, Cui Z, Zhao Y, Ma S, et al
    Candidate lncRNA-microRNA-mRNA networks in predicting non-small cell lung cancer and related prognosis analysis.
    J Cancer Res Clin Oncol. 2020 Mar 2. pii: 10.1007/s00432-020-03161.
    PubMed     Abstract available
    
    
    
84. LI Y, Qin Y
    Peri-operative chemotherapy for resectable colorectal lung metastasis: a systematic review and meta-analysis.
    J Cancer Res Clin Oncol. 2020;146:545-553.
    PubMed     Abstract available
    
    
    
85. LIU DH, Ye ZH, Chen S, Sun XS, et al
    Novel prognostic model for stratifying survival in stage I lung adenocarcinoma patients.
    J Cancer Res Clin Oncol. 2020;146:801-807.
    PubMed     Abstract available
    
    
    
86. QIN X, Wang H, Hu X, Gu X, et al
    Predictive models for patients with lung carcinomas to identify EGFR mutation status via an artificial neural network based on multiple clinical information.
    J Cancer Res Clin Oncol. 2020;146:767-775.
    PubMed     Abstract available
    
    
    February 2020
87. SHU Z, Dong B, Shi L, Shen W, et al
    Stereotactic body radiotherapy for elderly patients (>/= 75 years) with early-stage non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Feb 24. pii: 10.1007/s00432-020-03154.
    PubMed     Abstract available
    
    
    
88. MUHAMMAD T, Sakhawat A, Khan AA, Huang H, et al
    Aloperine in combination with therapeutic adenoviral vector synergistically suppressed the growth of non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Feb 22. pii: 10.1007/s00432-020-03157.
    PubMed     Abstract available
    
    
    
89. QIANG H, Chang Q, Xu J, Qian J, et al
    New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2020 Feb 17. pii: 10.1007/s00432-020-03129.
    PubMed     Abstract available
    
    
    
90. CASTELLO A, Toschi L, Rossi S, Mazziotti E, et al
    The immune-metabolic-prognostic index and clinical outcomes in patients with non-small cell lung carcinoma under checkpoint inhibitors.
    J Cancer Res Clin Oncol. 2020 Feb 11. pii: 10.1007/s00432-020-03150.
    PubMed     Abstract available
    
    
    
91. TAKADA K, Yoneshima Y, Tanaka K, Okamoto I, et al
    Clinical impact of skeletal muscle area in patients with non-small cell lung cancer treated with anti-PD-1 inhibitors.
    J Cancer Res Clin Oncol. 2020 Feb 5. pii: 10.1007/s00432-020-03146.
    PubMed     Abstract available
    
    
    
92. TANG Y, Che N, Yu Y, Gao Y, et al
    Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
    J Cancer Res Clin Oncol. 2020;146:407-416.
    PubMed     Abstract available
    
    
    
93. LANDRE T, Des Guetz G, Chouahnia K, Taleb C, et al
    First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
    J Cancer Res Clin Oncol. 2020;146:441-448.
    PubMed     Abstract available
    
    
    January 2020
94. SONG YQ, Wang N, Qiao Y, He L, et al
    Treatment patterns and survival after 18F-fluorodeoxyglucose positron emission tomography/computed tomography-guided local consolidation therapy for oligometastatic non-small cell lung cancer: a two-center propensity score-matched analysis.
    J Cancer Res Clin Oncol. 2020 Jan 25. pii: 10.1007/s00432-020-03134.
    PubMed     Abstract available
    
    
    
95. TIAN P, Liu Y, Zeng H, Tang Y, et al
    Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.
    J Cancer Res Clin Oncol. 2020 Jan 1. pii: 10.1007/s00432-019-03116.
    PubMed     Abstract available
    
    
    
96. LI W, Yu H
    Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
    J Cancer Res Clin Oncol. 2020;146:137-152.
    PubMed     Abstract available
    
    
    
97. LIU B, Chi W, Li X, Li P, et al
    Evolving the pulmonary nodules diagnosis from classical approaches to deep learning-aided decision support: three decades' development course and future prospect.
    J Cancer Res Clin Oncol. 2020;146:153-185.
    PubMed     Abstract available
    
    
    December 2019
98. IMAI H, Wasamoto S, Yamaguchi O, Suzuki K, et al
    Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged >/= 75 years) with non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2019 Dec 18. pii: 10.1007/s00432-019-03072.
    PubMed     Abstract available
    
    
    
99. KITADAI R, Okuma Y, Hakozaki T, Hosomi Y, et al
    The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases.
    J Cancer Res Clin Oncol. 2019 Dec 11. pii: 10.1007/s00432-019-03104.
    PubMed     Abstract available
    
    
    
100. YANG Z, Xu J, Li R, Gao Y, et al
     PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy.
     J Cancer Res Clin Oncol. 2019;145:3055-3065.
     PubMed     Abstract available
     
     
     November 2019
101. LUO J, Dai X, Hu H, Chen J, et al
     Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
     J Cancer Res Clin Oncol. 2019 Nov 30. pii: 10.1007/s00432-019-03097.
     PubMed     Abstract available
     
     
     
102. CHEN Z, Yin K, Zheng D, Gu J, et al
     Marital status independently predicts non-small cell lung cancer survival: a propensity-adjusted SEER database analysis.
     J Cancer Res Clin Oncol. 2019 Nov 30. pii: 10.1007/s00432-019-03084.
     PubMed     Abstract available
     
     
     
103. WANG BY, Huang JY, Chen HC, Lin CH, et al
     The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients.
     J Cancer Res Clin Oncol. 2019 Nov 8. pii: 10.1007/s00432-019-03079.
     PubMed     Abstract available
     
     
     
104. CHEN D, Xu J, Zhao Y, Chu T, et al
     Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
     J Cancer Res Clin Oncol. 2019 Nov 6. pii: 10.1007/s00432-019-03064.
     PubMed     Abstract available
     
     
     October 2019
105. JIANG Q, Yuan Y, Gong Y, Luo X, et al
     Therapeutic delivery of microRNA-143 by cationic lipoplexes for non-small cell lung cancer treatment in vivo.
     J Cancer Res Clin Oncol. 2019 Oct 25. pii: 10.1007/s00432-019-03051.
     PubMed     Abstract available
     
     
     
106. WANG Y, Liu Y, Zhang L, Tong L, et al
     Vimentin expression in circulating tumor cells (CTCs) associated with liver metastases predicts poor progression-free survival in patients with advanced lung cancer.
     J Cancer Res Clin Oncol. 2019 Oct 23. pii: 10.1007/s00432-019-03040.
     PubMed     Abstract available
     
     
     
107. XU Y, Huang Y, Weng L, Zheng J, et al
     Effects of single-nucleotide polymorphisms in the mTORC1 pathway on the risk of brain metastasis in patients with non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2019 Oct 22. pii: 10.1007/s00432-019-03059.
     PubMed     Abstract available
     
     
     
108. LI C, Zhang L, Meng G, Wang Q, et al
     Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2019 Oct 19. pii: 10.1007/s00432-019-03045.
     PubMed     Abstract available
     
     
     
109. SAAD M, Lee IH, Choi TS
     Are shape morphologies associated with survival? A potential shape-based biomarker predicting survival in lung cancer.
     J Cancer Res Clin Oncol. 2019 Oct 16. pii: 10.1007/s00432-019-03048.
     PubMed     Abstract available
     
     
     
110. NI Y, Ye X, Yang X, Huang G, et al
     Microwave ablation as local consolidative therapy for patients with extracranial oligometastatic EGFR-mutant non-small cell lung cancer without progression after first-line EGFR-TKIs treatment.
     J Cancer Res Clin Oncol. 2019 Oct 10. pii: 10.1007/s00432-019-03043.
     PubMed     Abstract available
     
     
     
111. DENG LL, Gao G, Deng HB, Wang F, et al
     Co-occurring genetic alterations predict distant metastasis and poor efficacy of first-line EGFR-TKIs in EGFR-mutant NSCLC.
     J Cancer Res Clin Oncol. 2019;145:2613-2624.
     PubMed     Abstract available
     
     
     September 2019
112. LIU L, Song X, Li X, Xue L, et al
     A three-platelet mRNA set: MAX, MTURN and HLA-B as biomarker for lung cancer.
     J Cancer Res Clin Oncol. 2019 Sep 24. pii: 10.1007/s00432-019-03032.
     PubMed     Abstract available
     
     
     
113. WANG A, Komiya T
     Brain metastasis as exclusion criteria in clinical trials involving extensive-stage small cell lung cancer.
     J Cancer Res Clin Oncol. 2019 Sep 23. pii: 10.1007/s00432-019-03034.
     PubMed     Abstract available
     
     
     
114. ZHOU C, Che G, Zheng X, Qiu J, et al
     Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2019 Sep 20. pii: 10.1007/s00432-019-03025.
     PubMed     Abstract available
     
     
     
115. MIHAJLOVIC J, Diehl LAM, Hochhaus A, Clement JH, et al
     Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells.
     J Cancer Res Clin Oncol. 2019 Sep 17. pii: 10.1007/s00432-019-03026.
     PubMed     Abstract available
     
     
     
116. OTA T, Kirita K, Matsuzawa R, Udagawa H, et al
     Validity of using immunohistochemistry to predict treatment outcome in patients with non-small cell lung cancer not otherwise specified.
     J Cancer Res Clin Oncol. 2019 Sep 7. pii: 10.1007/s00432-019-03012.
     PubMed     Abstract available
     
     
     
117. OSTHEIMER C, Evers C, Palm F, Mikolajczyk R, et al
     Mortality after radiotherapy or surgery in the treatment of early stage non-small-cell lung cancer: a population-based study on recent developments.
     J Cancer Res Clin Oncol. 2019 Sep 6. pii: 10.1007/s00432-019-03013.
     PubMed     Abstract available
     
     
     
118. SUN S, Hu Z, Huang S, Ye X, et al
     REG4 is an indicator for KRAS mutant lung adenocarcinoma with TTF-1 low expression.
     J Cancer Res Clin Oncol. 2019;145:2273-2283.
     PubMed     Abstract available
     
     
     
119. ITO M, Miyata Y, Hirano S, Kimura S, et al
     Synchronicity of genetic variants between primary sites and metastatic lymph nodes, and prognostic impact in nodal metastatic lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2019;145:2325-2333.
     PubMed     Abstract available
     
     
     
120. SONG T, Jiang L, Zhuo Z, Luo J, et al
     Impacts of thoracoscopic surgery and high grade histologic subtypes on spread through air spaces in small stage I lung adenocarcinomas.
     J Cancer Res Clin Oncol. 2019;145:2375-2382.
     PubMed     Abstract available
     
     
     August 2019
121. CHEN B, Xia W, Wang Z, Zhao H, et al
     Risk analyses of N2 lymph-node metastases in patients with T1 non-small cell lung cancer: a multi-center real-world observational study in China.
     J Cancer Res Clin Oncol. 2019 Aug 19. pii: 10.1007/s00432-019-03006.
     PubMed     Abstract available
     
     
     
122. ZHANG H, Deng L, Wang X, Wang D, et al
     Metastatic location of extensive stage small-cell lung cancer: implications for thoracic radiation.
     J Cancer Res Clin Oncol. 2019 Aug 13. pii: 10.1007/s00432-019-03000.
     PubMed     Abstract available
     
     
     
123. HOTZEL J, Melling N, Muller J, Polonski A, et al
     Protein expression of close homologue of L1 (CHL1) is a marker for overall survival in non-small cell lung cancer (NSCLC).
     J Cancer Res Clin Oncol. 2019 Aug 1. pii: 10.1007/s00432-019-02989.
     PubMed     Abstract available
     
     
     
124. HORN LC, Hohn AK, Stark S, Einenkel J, et al
     Endocervical adenocarcinoma in situ (AIS) with ovarian and pulmonary involvement: report of a case and review of the literature suggesting a "seed and soil hypothesis".
     J Cancer Res Clin Oncol. 2019;145:2061-2069.
     PubMed     Abstract available
     
     
     
125. HAN H, Zhao Y, Gao Z, Zheng D, et al
     A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy.
     J Cancer Res Clin Oncol. 2019;145:2115-2122.
     PubMed     Abstract available
     
     
     July 2019
126. HAKOZAKI T, Okuma Y, Hashimoto K, Hosomi Y, et al
     Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.
     J Cancer Res Clin Oncol. 2019 Jul 26. pii: 10.1007/s00432-019-02985.
     PubMed     Abstract available
     
     
     
127. LI Y, Hu S, Xie J, Zhang X, et al
     Effects of surgery on survival of elderly patients with stage I small-cell lung cancer: analysis of the SEER database.
     J Cancer Res Clin Oncol. 2019 Jul 13. pii: 10.1007/s00432-019-02976.
     PubMed     Abstract available
     
     
     
128. SHEN J, Xu J, Chen B, Ma D, et al
     Elevated integrin alpha6 expression is involved in the occurrence and development of lung adenocarcinoma, and predicts a poor prognosis: a study based on immunohistochemical analysis and bioinformatics.
     J Cancer Res Clin Oncol. 2019;145:1681-1693.
     PubMed     Abstract available
     
     
     
129. OMORI T, Aokage K, Nakamura H, Katsumata S, et al
     Growth patterns of small peripheral squamous cell carcinoma of the lung and their impacts on pathological and biological characteristics of tumor cells.
     J Cancer Res Clin Oncol. 2019;145:1773-1783.
     PubMed     Abstract available
     
     
     June 2019
130. TSYGANOV MM, Pevzner AM, Ibragimova MK, Deryusheva IV, et al
     Human papillomavirus and lung cancer: an overview and a meta-analysis.
     J Cancer Res Clin Oncol. 2019 Jun 24. pii: 10.1007/s00432-019-02960.
     PubMed     Abstract available
     
     
     
131. PARK CK, Kim JE, Kim MS, Kho BG, et al
     Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2019 Jun 1. pii: 10.1007/s00432-019-02944.
     PubMed     Abstract available
     
     
     
132. KOH YW, Han JH, Haam S, Jung J, et al
     ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data.
     J Cancer Res Clin Oncol. 2019;145:1427-1436.
     PubMed     Abstract available
     
     
     
133. SCHULER M, Tan EH, O'Byrne K, Zhang L, et al
     First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
     J Cancer Res Clin Oncol. 2019;145:1569-1579.
     PubMed     Abstract available
     
     
     May 2019
134. PARK JH, Kwon BS, Park SJ, Ji W, et al
     Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2019 May 29. pii: 10.1007/s00432-019-02941.
     PubMed     Abstract available
     
     
     
135. CHO JH, Jung HA, Lee SH, Ahn JS, et al
     Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
     J Cancer Res Clin Oncol. 2019;145:1341-1349.
     PubMed     Abstract available
     
     
     April 2019
136. ZHU J, Liu W, Chen C, Zhang H, et al
     TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells.
     J Cancer Res Clin Oncol. 2019 Apr 23. pii: 10.1007/s00432-019-02921.
     PubMed     Abstract available
     
     
     
137. CHENG X, Yin H, Fu J, Chen C, et al
     Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma.
     J Cancer Res Clin Oncol. 2019;145:1027-1035.
     PubMed     Abstract available
     
     
     
138. MELLING N, Bachmann K, Hofmann B, El Gammal AT, et al
     Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.
     J Cancer Res Clin Oncol. 2019;145:873-879.
     PubMed     Abstract available
     
     
     
139. WANG L, Liu J, Liu J, Chen X, et al
     GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
     J Cancer Res Clin Oncol. 2019;145:861-872.
     PubMed     Abstract available
     
     
     March 2019
140. HAWKINS PG, Sun Y, Dess RT, Jackson WC, et al
     Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer.
     J Cancer Res Clin Oncol. 2019 Mar 28. pii: 10.1007/s00432-019-02903.
     PubMed     Abstract available
     
     
     
141. AHN BC, Pyo KH, Xin CF, Jung D, et al
     Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
     J Cancer Res Clin Oncol. 2019 Mar 25. pii: 10.1007/s00432-019-02899.
     PubMed     Abstract available
     
     
     
142. CHANG H, Lee SJ, Lim J, Lee JS, et al
     Prognostic significance of metabolic parameters measured by (18)F-FDG PET/CT in limited-stage small-cell lung carcinoma.
     J Cancer Res Clin Oncol. 2019 Mar 21. pii: 10.1007/s00432-019-02848.
     PubMed     Abstract available
     
     
     
143. FANG L, Wang L, Wang Y, Wu Y, et al
     Predictors and survival impact of station 4L metastasis in left non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2019 Mar 16. pii: 10.1007/s00432-019-02880.
     PubMed     Abstract available
     
     
     
144. CAMPLING BG, Ye Z, Lai Y, Li L, et al
     Disparity in age at lung cancer diagnosis between current and former smokers.
     J Cancer Res Clin Oncol. 2019 Mar 4. pii: 10.1007/s00432-019-02875.
     PubMed     Abstract available
     
     
     
145. ZHANG Y, Ma Y, Li Y, Shen X, et al
     Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations.
     J Cancer Res Clin Oncol. 2019;145:747-757.
     PubMed     Abstract available
     
     
     
146. SONG Q, Shang J, Zhang C, Zhang L, et al
     Impact of the homogeneous and heterogeneous risk factors on the incidence and survival outcome of bone metastasis in NSCLC patients.
     J Cancer Res Clin Oncol. 2019;145:737-746.
     PubMed     Abstract available
     
     
     February 2019
147. LIN XR, Zhou XL, Feng Q, Pan XY, et al
     CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.
     J Cancer Res Clin Oncol. 2019 Feb 22. pii: 10.1007/s00432-019-02857.
     PubMed     Abstract available
     
     
     
148. PARK HL, Yoo IR, Boo SH, Park SY, et al
     Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
     J Cancer Res Clin Oncol. 2019 Feb 13. pii: 10.1007/s00432-019-02858.
     PubMed     Abstract available
     
     
     
149. MENG D, Meng M, Luo A, Jing X, et al
     Effects of VEGFR1(+) hematopoietic progenitor cells on pre-metastatic niche formation and in vivo metastasis of breast cancer cells.
     J Cancer Res Clin Oncol. 2019;145:411-427.
     PubMed     Abstract available
     
     
     
150. MIYASHITA T, Omori T, Nakamura H, Sugano M, et al
     Spatiotemporal characteristics of fibroblasts-dependent cancer cell invasion.
     J Cancer Res Clin Oncol. 2019;145:373-381.
     PubMed     Abstract available
     
     
     January 2019
151. PENG F, Li Q, Niu SQ, Shen GP, et al
     ZWINT is the next potential target for lung cancer therapy.
     J Cancer Res Clin Oncol. 2019 Jan 14. pii: 10.1007/s00432-018-2823.
     PubMed     Abstract available
     
     
     
152. ZHANG J, Xiang C, Han Y, Teng H, et al
     Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry.
     J Cancer Res Clin Oncol. 2019;145:269-279.
     PubMed     Abstract available
     
     
     
153. LIU C, Li Z, Wang S, Fan Y, et al
     FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2019;145:65-76.
     PubMed     Abstract available
     
     
     December 2018
154. ZHUGE L, Huang Y, Wang S, Xie J, et al
     Preoperative brain MRI for clinical stage IA lung cancer: is routine scanning rational?
     J Cancer Res Clin Oncol. 2018 Dec 7. pii: 10.1007/s00432-018-2814.
     PubMed     Abstract available
     
     
     
155. RICCIUTI B, Genova C, De Giglio A, Bassanelli M, et al
     Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
     J Cancer Res Clin Oncol. 2018 Dec 1. pii: 10.1007/s00432-018-2805.
     PubMed     Abstract available
     
     
     November 2018
156. WANG J, Wu N, Lv C, Yan S, et al
     Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
     J Cancer Res Clin Oncol. 2018 Nov 24. pii: 10.1007/s00432-018-2801.
     PubMed     Abstract available
     
     
     
157. THORLACIUS-USSING J, Kehlet SN, Ronnow SR, Karsdal MA, et al
     Non-invasive profiling of protease-specific elastin turnover in lung cancer: biomarker potential.
     J Cancer Res Clin Oncol. 2018 Nov 22. pii: 10.1007/s00432-018-2799.
     PubMed     Abstract available
     
     
     
158. GUO T, Li J, Zhang L, Hou W, et al
     Multidimensional communication of microRNAs and long non-coding RNAs in lung cancer.
     J Cancer Res Clin Oncol. 2018 Nov 11. pii: 10.1007/s00432-018-2767.
     PubMed     Abstract available
     
     
     
159. ZOU SM, Li WH, Wang WM, Li WB, et al
     The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
     J Cancer Res Clin Oncol. 2018;144:2149-2159.
     PubMed     Abstract available
     
     
     October 2018
160. KORDIAK J, Szemraj J, Grabska-Kobylecka I, Bialasiewicz P, et al
     Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.
     J Cancer Res Clin Oncol. 2018 Oct 27. pii: 10.1007/s00432-018-2779.
     PubMed     Abstract available
     
     
     
161. YANG H, Xu J, Yao F, Liang S, et al
     Analysis of unexpected small cell lung cancer following surgery as the primary treatment.
     J Cancer Res Clin Oncol. 2018 Oct 20. pii: 10.1007/s00432-018-2766.
     PubMed     Abstract available
     
     
     
162. YAN X, Wang Q, Wang H, Li P, et al
     Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
     J Cancer Res Clin Oncol. 2018 Oct 6. pii: 10.1007/s00432-018-2764.
     PubMed     Abstract available
     
     
     September 2018
163. STRATMANN JA, Michels S, Hornetz S, Christoph DC, et al
     Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2018 Sep 22. pii: 10.1007/s00432-018-2754.
     PubMed     Abstract available
     
     
     
164. DE OLIVEIRA THA, do Amaral CM, de Franca Sao Marcos B, Nascimento KCG, et al
     Presence and activity of HPV in primary lung cancer.
     J Cancer Res Clin Oncol. 2018 Sep 17. pii: 10.1007/s00432-018-2748.
     PubMed     Abstract available
     
     
     August 2018
165. LENG Q, Tsou JH, Zhan M, Jiang F, et al
     Fucosylation genes as circulating biomarkers for lung cancer.
     J Cancer Res Clin Oncol. 2018 Aug 12. pii: 10.1007/s00432-018-2735.
     PubMed     Abstract available
     
     
     
166. STUMPF C, Kaemmerer D, Neubauer E, Sanger J, et al
     Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.
     J Cancer Res Clin Oncol. 2018 Aug 3. pii: 10.1007/s00432-018-2722.
     PubMed     Abstract available
     
     
     
167. LIU XL, Zuo R, Ou WB
     The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.
     J Cancer Res Clin Oncol. 2018 Aug 3. pii: 10.1007/s00432-018-2727.
     PubMed     Abstract available
     
     
     July 2018
168. FAEHLING M, Schwenk B, Kramberg S, Fallscheer S, et al
     Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice.
     J Cancer Res Clin Oncol. 2018 Jul 30. pii: 10.1007/s00432-018-2714.
     PubMed     Abstract available
     
     
     
169. ZHANG Y, Zhang M, Jiang Y, Li X, et al
     Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China.
     J Cancer Res Clin Oncol. 2018 Jul 24. pii: 10.1007/s00432-018-2718.
     PubMed     Abstract available
     
     
     
170. QIU J, Li X, He Y, Sun D, et al
     Distinct subgroup of the Ras family member 3 (DIRAS3) expression impairs metastasis and induces autophagy of gastric cancer cells in mice.
     J Cancer Res Clin Oncol. 2018 Jul 24. pii: 10.1007/s00432-018-2708.
     PubMed     Abstract available
     
     
     
171. LUO W, Wang Z, Tian P, Li W, et al
     Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
     J Cancer Res Clin Oncol. 2018 Jul 17. pii: 10.1007/s00432-018-2707.
     PubMed     Abstract available
     
     
     
172. YANG J, Zhang Y, Sun X, Gusdon AM, et al
     The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study.
     J Cancer Res Clin Oncol. 2018 Jul 12. pii: 10.1007/s00432-018-2702.
     PubMed     Abstract available
     
     
     
173. PENG Y, Chen Y, Zhang X, Yang Y, et al
     Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
     J Cancer Res Clin Oncol. 2018;144:1339-1346.
     PubMed     Abstract available
     
     
     June 2018
174. OKUMA Y, Kashima J, Watanabe K, Homma S, et al
     Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
     J Cancer Res Clin Oncol. 2018 Jun 1. pii: 10.1007/s00432-018-2681.
     PubMed     Abstract available
     
     
     
175. LI C, Liu H, Zhang B, Gong L, et al
     Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors.
     J Cancer Res Clin Oncol. 2018;144:1079-1086.
     PubMed     Abstract available
     
     
     
176. WANG Y, Zheng D, Zheng J, Huang Q, et al
     Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy.
     J Cancer Res Clin Oncol. 2018;144:1015-1023.
     PubMed     Abstract available
     
     
     May 2018
177. ZHU Y, Tang K, Zhao F, Zang Y, et al
     End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer.
     J Cancer Res Clin Oncol. 2018 May 29. pii: 10.1007/s00432-018-2673.
     PubMed     Abstract available
     
     
     
178. XU J, Zhao X, He D, Wang J, et al
     Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
     J Cancer Res Clin Oncol. 2018 May 24. pii: 10.1007/s00432-018-2668.
     PubMed     Abstract available
     
     
     
179. HU C, Zhu P, Xia Y, Hui K, et al
     Role of the NRP-1-mediated VEGFR2-independent pathway on radiation sensitivity of non-small cell lung cancer cells.
     J Cancer Res Clin Oncol. 2018 May 17. pii: 10.1007/s00432-018-2667.
     PubMed     Abstract available
     
     
     
180. HANKE NT, Imler E, Marron MT, Seligmann BE, et al
     Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
     J Cancer Res Clin Oncol. 2018 May 15. pii: 10.1007/s00432-018-2662.
     PubMed     Abstract available
     
     
     
181. MEIER-SCHROERS M, Schild HH, Thomas D
     Response to "Commentary on: Lung cancer screening with MRI: results of the first screening round": Ngam Pei Ing et al.
     J Cancer Res Clin Oncol. 2018 May 14. pii: 10.1007/s00432-018-2660.
     PubMed    
     
     
     
182. NGAM PI, Ling JZJ
     "Commentary on: Lung cancer screening with MRI: results of the first screening round"-Michael Meier-Schroers et al.
     J Cancer Res Clin Oncol. 2018 May 10. pii: 10.1007/s00432-018-2655.
     PubMed    
     
     
     
183. BOYARSKIKH UA, Shadrina AS, Smetanina MA, Tsepilov YA, et al
     Mycoplasma hyorhinis reduces sensitivity of human lung carcinoma cells to Nutlin-3 and promotes their malignant phenotype.
     J Cancer Res Clin Oncol. 2018 May 8. pii: 10.1007/s00432-018-2658.
     PubMed     Abstract available
     
     
     
184. WANG K, Qu X, Liu S, Yang X, et al
     Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma.
     J Cancer Res Clin Oncol. 2018 May 4. pii: 10.1007/s00432-018-2653.
     PubMed     Abstract available
     
     
     
185. NAKASONE S, Mimaki S, Ichikawa T, Aokage K, et al
     Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2018;144:893-900.
     PubMed     Abstract available
     
     
     
186. ZHANG L, Li J, Lv X, Guo T, et al
     MID1-PP2A complex functions as new insights in human lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2018;144:855-864.
     PubMed     Abstract available
     
     
     
187. UEDA T, Aokage K, Nishikawa H, Neri S, et al
     Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung.
     J Cancer Res Clin Oncol. 2018;144:835-844.
     PubMed     Abstract available
     
     
     April 2018
188. FAEHLING M, Achenbach J, Staib P, Steffen U, et al
     Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).
     J Cancer Res Clin Oncol. 2018 Apr 23. pii: 10.1007/s00432-018-2649.
     PubMed     Abstract available
     
     
     
189. ROJKO L, Reiniger L, Teglasi V, Fabian K, et al
     Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
     J Cancer Res Clin Oncol. 2018 Apr 19. pii: 10.1007/s00432-018-2642.
     PubMed     Abstract available
     
     
     
190. ELSAYAD K, Samhouri L, Scobioala S, Haverkamp U, et al
     Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer?
     J Cancer Res Clin Oncol. 2018 Apr 5. pii: 10.1007/s00432-018-2640.
     PubMed     Abstract available
     
     
     
191. AKTAS ON, Ozturk AB, Erman B, Erus S, et al
     Role of natural killer cells in lung cancer.
     J Cancer Res Clin Oncol. 2018 Apr 3. pii: 10.1007/s00432-018-2635.
     PubMed     Abstract available
     
     
     
192. YUAN Y, Ma G, Zhang Y, Chen H, et al
     Presence of micropapillary and solid patterns are associated with nodal upstaging and unfavorable prognosis among patient with cT1N0M0 lung adenocarcinoma: a large-scale analysis.
     J Cancer Res Clin Oncol. 2018;144:743-749.
     PubMed     Abstract available
     
     
     
193. LI J, You W, Zheng D, Yan B, et al
     A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component.
     J Cancer Res Clin Oncol. 2018;144:725-734.
     PubMed     Abstract available
     
     
     March 2018
194. SIKARIA D, Tu YN, Fisler DA, Mauro JA, et al
     Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma.
     J Cancer Res Clin Oncol. 2018;144:459-468.
     PubMed     Abstract available
     
     
     
195. XU X, Yu S, Sun W, Qin X, et al
     MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment.
     J Cancer Res Clin Oncol. 2018;144:431-438.
     PubMed     Abstract available
     
     
     January 2018
196. JIANG MM, Mai ZT, Wan SZ, Chi YM, et al
     Microarray profiles reveal that circular RNA hsa_circ_0007385 functions as an oncogene in non-small cell lung cancer tumorigenesis.
     J Cancer Res Clin Oncol. 2018 Jan 25. pii: 10.1007/s00432-017-2576.
     PubMed     Abstract available
     
     
     
197. MATSUO Y, Shiomi K, Sonoda D, Mikubo M, et al
     Molecular alterations in a new cell line (KU-Lu-MPPt3) established from a human lung adenocarcinoma with a micropapillary pattern.
     J Cancer Res Clin Oncol. 2018;144:75-87.
     PubMed     Abstract available
     
     
     
198. ZHANG Y, Ma Y, Li Y, Shen X, et al
     Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
     J Cancer Res Clin Oncol. 2018;144:165-171.
     PubMed     Abstract available
     
     
     
199. KIRCHBERGER MC, Schilling B, Haferkamp S, Bosserhoff A, et al
     Can checkpoint inhibitor therapy improve response to chemotherapy?
     J Cancer Res Clin Oncol. 2018;144:183-185.
     PubMed    
     
     
     December 2017
200. XU X, Li N, Zhao R, Zhu L, et al
     Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ.
     J Cancer Res Clin Oncol. 2017;143:2447-2453.
     PubMed     Abstract available
     
     
     November 2017
201. JIA PL, Zhang C, Yu JJ, Xu C, et al
     The risk of lung cancer among cooking adults: a meta-analysis of 23 observational studies.
     J Cancer Res Clin Oncol. 2017 Nov 21. doi: 10.1007/s00432-017-2547.
     PubMed     Abstract available
     
     
     
202. XIONG Y, Wang L, Wang S, Wang M, et al
     SIRT3 deacetylates and promotes degradation of P53 in PTEN-defective non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2017 Nov 4. doi: 10.1007/s00432-017-2537.
     PubMed     Abstract available
     
     
     
203. KIM HR, Kim SY, Kim CH, Yang SH, et al
     Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis.
     J Cancer Res Clin Oncol. 2017;143:2283-2290.
     PubMed     Abstract available
     
     
     October 2017
204. WEI S, Tian J, Song X, Wu B, et al
     Causes of death and competing risk analysis of the associated factors for non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database.
     J Cancer Res Clin Oncol. 2017 Oct 4. doi: 10.1007/s00432-017-2522.
     PubMed     Abstract available
     
     
     
205. WANG Y, Wang R, Zheng D, Han B, et al
     The indication of completion lobectomy for lung adenocarcinoma </=3 cm after wedge resection during surgical operation.
     J Cancer Res Clin Oncol. 2017;143:2095-2104.
     PubMed     Abstract available
     
     
     
206. POWROZEK T, Mlak R, Dziedzic M, Malecka-Massalska T, et al
     Analysis of primary-miRNA-3662 and its mature form may improve detection of the lung adenocarcinoma.
     J Cancer Res Clin Oncol. 2017;143:1941-1946.
     PubMed     Abstract available
     
     
     September 2017
207. MEIER-SCHROERS M, Homsi R, Skowasch D, Buermann J, et al
     Lung cancer screening with MRI: results of the first screening round.
     J Cancer Res Clin Oncol. 2017 Sep 20. doi: 10.1007/s00432-017-2521.
     PubMed     Abstract available
     
     
     
208. THULER LCS, Costa GJ, de Mello MJG, Ferreira CG, et al
     Response to "Commentary on: Undertreatment trend in elderly lung cancer patients in Brazil"-Jing-lan Tang, Chun-jie Hou.
     J Cancer Res Clin Oncol. 2017 Sep 5. doi: 10.1007/s00432-017-2511.
     PubMed    
     
     
     
209. TAO H, Zhang Y, Li Q, Chen J, et al
     Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review.
     J Cancer Res Clin Oncol. 2017 Sep 5. doi: 10.1007/s00432-017-2516.
     PubMed     Abstract available
     
     
     August 2017
210. TANG JL, Hou CJ
     Commentary on: undertreatment trend in elderly lung cancer patients in Brazil.
     J Cancer Res Clin Oncol. 2017 Aug 29. doi: 10.1007/s00432-017-2498.
     PubMed    
     
     
     
211. GU C, Wang R, Pan X, Huang Q, et al
     Sublobar resection versus lobectomy in patients aged </=35 years with stage IA non-small cell lung cancer: a SEER database analysis.
     J Cancer Res Clin Oncol. 2017 Aug 17. doi: 10.1007/s00432-017-2499.
     PubMed     Abstract available
     
     
     
212. LIAO YH, Li CI, Lin CC, Lin JG, et al
     Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients.
     J Cancer Res Clin Oncol. 2017 Aug 12. doi: 10.1007/s00432-017-2491.
     PubMed     Abstract available
     
     
     
213. MININA VI, Soboleva OA, Glushkov AN, Voronina EN, et al
     Polymorphisms of GSTM1, GSTT1, GSTP1 genes and chromosomal aberrations in lung cancer patients.
     J Cancer Res Clin Oncol. 2017 Aug 2. doi: 10.1007/s00432-017-2486.
     PubMed     Abstract available
     
     
     
214. HASHIMOTO H, Suda Y, Miyashita T, Ochiai A, et al
     A novel method to generate single-cell-derived cancer-associated fibroblast clones.
     J Cancer Res Clin Oncol. 2017;143:1409-1419.
     PubMed     Abstract available
     
     
     May 2017
215. WU X, Ma W, Zhou Q, Yan H, et al
     AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases.
     J Cancer Res Clin Oncol. 2017 May 27. doi: 10.1007/s00432-017-2408.
     PubMed     Abstract available
     
     
     April 2017
216. WIECZOREK SA, Breitenbuecher F, Soni A, Paul-Konietzko K, et al
     Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancer.
     J Cancer Res Clin Oncol. 2017 Apr 21. doi: 10.1007/s00432-017-2427.
     PubMed     Abstract available
     
     
     
217. COSTA GJ, de Mello MJ, Ferreira CG, Thuler LC, et al
     Undertreatment trend in elderly lung cancer patients in Brazil.
     J Cancer Res Clin Oncol. 2017 Apr 7. doi: 10.1007/s00432-017-2412.
     PubMed     Abstract available
     
     
     
218. TAO H, Tanaka T, Okabe K
     Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
     J Cancer Res Clin Oncol. 2017 Apr 5. doi: 10.1007/s00432-017-2405.
     PubMed     Abstract available
     
     
     March 2017
219. HASTINGS RH, Montgrain PR, Quintana RA, Chobrutskiy B, et al
     Lung carcinoma progression and survival versus amino- and carboxyl-parathyroid hormone-related protein expression.
     J Cancer Res Clin Oncol. 2017 Mar 25. doi: 10.1007/s00432-017-2396.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: